Trending >

Promis Neurosciences could score with out-licensing deals, says Mackie Research

Elliot Goldstein
In an update to clients on Wednesday, Mackie Research analyst André Uddin gives a review of Promis Neurosciences’ (Promis Neurosciences Stock Quote, Chart TSX:PMN) discovery and pre-clinical-stage drug candidates and contends that a number of pharma companies are currently interested in out-licensing deals with PMN.

Promis is a pre-clinical-stage neurodegenerative disease biotech company whose lead drug candidate is PMN310, a potentially best-in-class Alzheimer’s drug.

Leaving aside PMN310 in his report, Uddin points to four groups of potential candidates: (1) PMN’s several anti-SOD1 mAb candidates currently in pre-clinical studies; (2) PMN’s TDP43 program which is currently in the lead candidate selection stage; (3) PMN’s the α- synuclein project, for which the company is currently in the lead candidate selection stage; and (4) the tau protein, for which PMN has identified several areas to target.

Uddin says that a monetization opportunity awaits for Promis.

“We expect PMN to out-license these targets/candidates. Very significant licensing deals have been forged by big pharma for the drug targets PMN is focused on. We expect a licensing deal to be forged in Q2 or Q3 2019 – multiple players are currently at the table – to be conservative, we are not assuming any transaction in our model at this time,” says Uddin on Wednesday.

The analyst is maintaining his “Speculative Buy” rating for PMN with a price target of $0.50, representing a projected 12-month return of 56 per cent at the time of publication.

______________________________________________________
An Engine for MedTech Innovation

This article is brought to you by Relay Medical Corp. (CSE:RELA)

 

 

Relay Medical is an integrated incubator/accelerator platform, developing a portfolio of medical technologies for pre-commercial exits in the Healthtech marketplace. Click on the logo for more info on this up-and-coming company…

 

___________________________________________________________

  •  
  •  
  •  

About The Author /

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Cantech Alerts.

Timely picks from Canada's best analysts. 

F                                                                      
close-link